Clinical trial
A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support
NCT00003942 is registered in ClinicalTrials.gov with Systemix as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support
- Lead sponsor
- Systemix
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- November 30, 1998
- Completion date
- Not reported
- Enrollment
- 15 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.